Biogen Pays $50 million to Reduce Future Royalty Payments on Alzheimer’s Drug Aducanumab

Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.